A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Novavax can ...
Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season "With today's approval, we will work with our partner Sanofi to provide ...
Novavax has successfully achieved U.S. BLA approval and completed both EU and U.S. marketing authorization transfers for Nuvaxovid to Sanofi in line with its CLA ...
There may soon be another COVID-19 vaccine on the market in the U.S. Novavax announced Monday that it has submitted a request to the Food and Drug Administration for emergency use authorization for ...
Novavax (NASDAQ:NVAX) has received regulatory approval in Japan for its COVID-19 vaccine, Nuvaxovid, which has resulted in a milestone payment from Takeda (NYSE:TAK) (OTCPK:TKPHF), the company said on ...
The U.S. Food and Drug Administration approved 2025-26 COVID-19 vaccines for anyone age 65 and older and any person 6 months and older who has at least one underlying health condition that increases ...
Sept 15 (Reuters) - U.S. drug developer Novavax Inc (NVAX.O), opens new tab said on Tuesday it was doubling its potential COVID-19 vaccine manufacturing capacity to two billion doses annually under an ...
Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback